Treatment of chronic hepatitis C.

Détails

ID Serval
serval:BIB_928A5F187B26
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Treatment of chronic hepatitis C.
Périodique
Minerva Medica
Auteur⸱e⸱s
Bihl F., Negro F.
ISSN
0026-4806
Statut éditorial
Publié
Date de publication
2009
Volume
100
Numéro
6
Pages
459-465
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Treatment for chronic hepatitis C has changed over the past years achieving higher response rates. The combination treatment with pegylated interferon-a and ribavirin is tailored based on the on-treatment virological responses. With this response-guided therapy, the overall sustained virological response rate is about 55%. Many new antivirals are currently under investigation and some will be commercially available in the near future. These include antiviral molecules acting directly against the hepatitis C virus (HCV) replication machinery, such as the inhibitors of the viral protease, and agents binding to host cofactors of the viral replication, thereby inhibiting HCV in an indirect way (such as cyclophilin inhibitors and nitazoxanide). The advent of these drugs will further ameliorate response rates and facilitate the permanent cure of chronic hepatitis C.
Pubmed
Web of science
Création de la notice
11/02/2010 16:42
Dernière modification de la notice
20/08/2019 14:55
Données d'usage